Similarly, elevated expression of PDLIM1 was associated with a reduced invasive ability of colorectal (40) and hepatocellular cancer cells (41), which coincides with the mesenchymal phenotype of therapy-induced persistence. Here, PDLIM1 is linked to hepatocellular carcinoma.